Sun Pharma Q2 FY27 Results: Revenue, Profit, Sales & Key Updates
Sun Pharmaceutical Industries reported consolidated revenue from operations of ₹16,198.71 crore in Q2 FY27, up 11.9% year on year (YoY). Consolidated net profit declined 36.2% to ₹1,988.53 crore, compared with ₹3,117.95 crore in the corresponding quarter of the previous financial year. The quarter ended on 30 September 2026.
Sun Pharma’s Q2 FY27 Earnings
| Financial Metric | Q2 FY27 | Q2 FY26 | YoY Change |
|---|---|---|---|
| Consolidated revenue from operations | ₹16,198.71 crore | ₹14,478.31 crore | +11.9% |
| Consolidated net profit (PAT) | ₹1,988.53 crore | ₹3,117.95 crore | -36.2% |
Sun Pharma reported exceptional expenses of ₹1,268.8 crore during the quarter. These included expenses related to the proposed acquisition of Organon and the settlement of US generic pharmaceuticals pricing antitrust litigation. The charges contributed to the decline in reported net profit.
Business Performance & Key Metrics
| Operating Metric | Q2 FY27 | Previous Period / Reference |
|---|---|---|
| Consolidated revenue from operations | ₹16,198.71 crore | +11.9% YoY |
| Consolidated net profit | ₹1,988.53 crore | -36.2% YoY |
| Adjusted net profit | ₹3,162 crore | +1.4% YoY |
| EBITDA | ₹4,744 crore | +4.8% YoY |
| EBITDA margin | 29.3% | 31.3% in Q2 FY26 |
| India formulations sales | ₹5,552.3 crore | +17.3% YoY |
| US formulations sales | US$455 million | -8.2% YoY |
| Emerging markets formulations sales | US$350 million | +7.6% YoY |
| Research and development expenditure | ₹778.4 crore | 4.8% of sales |
Sun Pharma’s domestic formulations business recorded growth of 17.3%, while emerging markets sales increased 7.6%. US formulations’ sales declined 8.2% year on year. Research and development expenditure stood at ₹778.4 crore during the quarter.
Share Price Reaction After Q2 FY27 Results
| Results Metric | Value |
|---|---|
| Results announcement date | 30 October 2026 |
| Consolidated PAT | ₹1,988.53 crore |
| PAT growth YoY | -36.2% |
| Revenue growth YoY | +11.9% |
| Share price during afternoon trade (BSE) | ₹1,833.30 |
| Share price movement | +3.99% |
| Earnings call | 6:30 PM IST, 30 October 2026 |
Sun Pharma’s shares gained during afternoon trade on 30 October 2026 despite the decline in reported net profit. The company’s revenue growth, domestic formulations performance and adjusted profitability were among the factors investors considered. The management’s earnings call was scheduled for 6:30 PM IST on the results announcement date. Investors will focus on domestic and international sales, EBITDA margins, research and development expenditure, exceptional costs and the proposed Organon acquisition in the management commentary.
Sun Pharma vs Other Pharmaceutical Stocks
| Company | Revenue / Total Income (Q2 FY27) | PAT (Q2 FY27) | PAT Growth YoY |
|---|---|---|---|
| Sun Pharma | ₹16,198.71 crore (consolidated revenue from operations) | ₹1,988.53 crore (consolidated) | -36.2% |
| Cipla | Results awaited | Results awaited | — |
| Dr. Reddy’s Laboratories | Results awaited | Results awaited | — |
| Divi’s Laboratories | Results awaited | Results awaited | — |
Sun Pharma’s Quarterly Financial Performance
| Quarter | Revenue from Operations | PAT | Growth Highlight |
|---|---|---|---|
| Q2 FY27 | ₹16,198.71 crore (consolidated) | ₹1,988.53 crore (consolidated) | Revenue +11.9% YoY; PAT -36.2% YoY |
| Q1 FY27 | ₹15,299.9 crore (consolidated) | ₹2,901 crore (consolidated) | Revenue +10.5% YoY; PAT +27% YoY |
| Q2 FY26 | ₹14,478.31 crore (consolidated) | ₹3,117.95 crore (consolidated) | Base quarter for YoY comparison |
Sun Pharma reported sequential growth in consolidated revenue from operations in Q2 FY27 compared with Q1 FY27. However, reported PAT declined sequentially and year on year, reflecting the impact of exceptional items. The adjusted net profit of ₹3,162 crore provides an additional reference point for assessing the quarter’s underlying profitability.
Key Takeaways from Sun Pharma Q2 FY27 Results
- Consolidated revenue from operations: ₹16,198.71 crore, up 11.9% YoY.
- Consolidated PAT: ₹1,988.53 crore, down 36.2% YoY.
- Adjusted net profit: ₹3,162 crore, up 1.4% YoY.
- EBITDA: ₹4,744 crore, up 4.8% YoY.
- EBITDA margin: 29.3%, compared with 31.3% in Q2 FY26.
- India formulations’ sales: ₹5,552.3 crore, up 17.3% YoY.
- US formulations sales: US$455 million, down 8.2% YoY.
- Emerging markets formulations sales: US$350 million, up 7.6% YoY.
- Research and development expenditure: ₹778.4 crore, representing 4.8% of sales.
- Exceptional items: ₹1,269 crore, largely comprising a US generic-pricing antitrust litigation settlement and Organon acquisition-related costs.
- Key metrics to track: domestic and international sales growth, EBITDA margins, research and development expenditure, exceptional costs, adjusted profitability, and progress on the Organon acquisition.
Disclaimer
The information provided above is for informational and educational purposes only and should not be construed as investment advice, a recommendation to buy or sell Sun Pharma shares, or a guarantee of future performance. The financial results, operational metrics and peer comparisons are based on information available as of 30 October 2026 and may be subject to revisions or updates. Investors should refer to Sun Pharma’s official disclosures, investor presentation and BSE/NSE filings for the latest information.
